1. Аверьянов Ю.Н., Подчуфарова Е.В. Синдром беспокойных ног. Неврол. журн., 1997; 3: 12–16.
2. Левин О.С. Синдром беспокойных ног. Экстрапирамидные расстройства. Руководство по диагностике и лечению. Под ред. В.Н.Штока, И.А.Ивановой-Смоленской, О.С.Левина. М.: Медпресс-информ, 2002.
3. Allen RP, Picchietti D, Hening WA et al. Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the Restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101–19.
4. Allen RP,Walters AS, Montplaisir J et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165: 1286–92.
5. Garcia-Borreguero D. Allen RP, Kohnen R et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine–International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007; 8: 520–30.
6. Hening W,Walters AS, Allen RP et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: The REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004; 5: 237–46.
7. Hening WA, Allen RP, Chokroverty S et al (eds). Restless legs syndrome. Phyladelphia: Saunders 2009.
8. Hening WA, Allen RP,Washburn M et al. The four diagnostic criteria for the Restless Legs Syndrome are unable to exclude confounding conditions («mimics»). Sleep Med 2009; 10: 976–81.
9. Montplaisir J, Godbout R, Poirier G et al. Restless legs syndrome and periodic movements in sleep: physiopathology and treatment with L-DOPA. Clin Neuropharmacol 1986; 9: 456–63.
10. Montplaisir J, Fantini ML, Desautels A et al. Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 2006; 13: 1306–11.
11. Oertel WH, Stiasny-Kolster K, Bergtholdt B et al. Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007; 22: 213–19.
12. Oertel WH, Trenkwalder C, Zucconi M et al. State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord 2007; 22 (Suppl l): 
S. 466–75.
13. Phillips B, Young T, Finn L et al. Epidemiology of restless legs symptoms in adults. Arch Int Med 2000; 160: 2137–41.
14. Quilici S, Abrams KR, Nicolas A et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med 2008; 9715–26.
15. Sloand JA, Shelly MA, Feigin A et al. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004; 43: 663–70.
16. Sommer M, Bachmann CG, Liebetanz KM et al. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 2007; 115: 347–50.
17. The International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Disord 1995; 10 (5): 634–42.
18. Trenkwalder C, Henning WA, Montagna P et al. Treatment of restless legs syndrome: an evidence–based review and implications for clinical practice. Movement Disorders 2008; 23: 2267–302.
19. Trenkwalder C, Hogl B, Benes H et al. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med 2008; 9: 572–4.
20. Wang J, O’Reilly B, Venkataraman R et al. Efficacy of oral iron in patients with restless legs syndrome and a low–normal ferritin: A randomized, double-blind, placebo-controlled study. Sleep Med 2009; 10: 973–5.
21. Winkelman J.W., Sethi K.D., Kushida C.A., et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006; 67: 1034–9.

О.С.Левин 

Кафедра неврологии Российской медицинской академии последипломного образования, Центр экстрапирамидных заболеваний